- Home
- FGL vs NXTC Comparison
FGL vs NXTC Comparison
Compare FGL & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGL
- NXTC
- Stock Information
- Founded
- FGL 2021
- NXTC 2015
- Country
- FGL Malaysia
- NXTC United States
- Employees
- FGL N/A
- NXTC N/A
- Industry
- FGL
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- FGL
- NXTC Health Care
- Exchange
- FGL NYSE
- NXTC Nasdaq
- Market Cap
- FGL 22.5M
- NXTC 20.6M
- IPO Year
- FGL 2024
- NXTC 2019
- Fundamental
- Price
- FGL $1.38
- NXTC $0.40
- Analyst Decision
- FGL
- NXTC Strong Buy
- Analyst Count
- FGL 0
- NXTC 2
- Target Price
- FGL N/A
- NXTC $3.50
- AVG Volume (30 Days)
- FGL 66.4K
- NXTC 99.1K
- Earning Date
- FGL 12-17-2024
- NXTC 03-06-2025
- Dividend Yield
- FGL N/A
- NXTC N/A
- EPS Growth
- FGL 45.69
- NXTC N/A
- EPS
- FGL 0.04
- NXTC N/A
- Revenue
- FGL $23,268,519.00
- NXTC N/A
- Revenue This Year
- FGL N/A
- NXTC N/A
- Revenue Next Year
- FGL N/A
- NXTC N/A
- P/E Ratio
- FGL $36.30
- NXTC N/A
- Revenue Growth
- FGL 336.06
- NXTC N/A
- 52 Week Low
- FGL $1.21
- NXTC $0.35
- 52 Week High
- FGL $5.26
- NXTC $2.49
- Technical
- Relative Strength Index (RSI)
- FGL N/A
- NXTC 22.20
- Support Level
- FGL N/A
- NXTC $0.49
- Resistance Level
- FGL N/A
- NXTC $0.67
- Average True Range (ATR)
- FGL 0.00
- NXTC 0.09
- MACD
- FGL 0.00
- NXTC -0.02
- Stochastic Oscillator
- FGL 0.00
- NXTC 12.74
About FGL FOUNDER GROUP LTD
Founder Group Ltd acts as an end-to-end Engineering, Procurement, Construction, and Commissioning solutions provider for solar PV facilities in Malaysia. The segments of the company are large-scale solar projects and commercial and industrial (C&I) solar projects. Large-scale solar projects of the company are utility-scale solar PV power plants with installed generating capacity of 1 MWac or more, and C&I projects of the company are smaller-scale solar projects where the solar PV systems are installed on rooftops and are designed to generate electricity for commercial and industrial properties for their consumption at factories, warehouses, and commercial stores. The company derives its revenue from Malaysia.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.